Clinical Trials Logo

Clinical Trial Summary

Buprenorphine is an important alternative to methadone in the maintenance treatment of heroin addiction. Transfer from methadone to buprenorphine requires a reduction of daily methadone dosage below 30 mg to avoid withdrawal after the first buprenorphine intake. The study hypothesis states that the transfer from a daily methadone dosage between 60 mg and 100 mg to buprenorphine can be carried out without withdrawal using buprenorphine patches (35 micro grams per hour) within 12 to 48 hours after last methadone intake.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00750217
Study type Interventional
Source Psychiatric University Hospital, Zurich
Contact
Status Unknown status
Phase Phase 4
Start date August 2008
Completion date May 2009

See also
  Status Clinical Trial Phase
Completed NCT02062723 - Observational Study to Assess the Efficacy and Tolerability of Eptadone®, in Heroin Addicted Patients in a MMT N/A
Completed NCT01580163 - Efficacy Evaluation of Traditional Chinese Medicine JITAI Combined Comprehensive Model Among Heroin Addicts After Detoxification N/A
Completed NCT00574067 - Buprenorphine for Prisoners Phase 3
Completed NCT00378079 - Methadone Maintenance for Prisoners Phase 3
Completed NCT01457872 - Malmö Treatment Referral and Intervention Study N/A
Active, not recruiting NCT04086459 - PET/MRI Study on the Neurological Mechanism of rTMS Treatment for Heroin Addiction N/A
Recruiting NCT01093248 - Methadone Maintenance Treatment Outcome Study in Taiwan N/A
Completed NCT02062736 - Observational Study to Assess the Adequacy of Methadone Dosage, in Heroin Addicted Patients in a MMT. N/A
Not yet recruiting NCT01668732 - Decision Making Deficit and DNA Methylation in Opioid Receptor Genes Among Community Heroin Addicts N/A